AnaptysBio shifts fiscal year-end to June 30
AnaptysBio, Inc. is changing its fiscal year-end from December 31 to June 30, as approved by its board of directors on May 18, 2026.
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
AnaptysBio, Inc. is changing its fiscal year-end from December 31 to June 30, as approved by its board of directors on May 18, 2026. The next fiscal year will begin on July 1, 2026.
The company will file a transition Form 10-KT covering the six-month period from January 1, 2026 through June 30, 2026, then begin filing quarterly reports based on the new fiscal year, starting with the quarter ending September 30, 2026.
8-K Event Classification
Item 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
1 item
Item 5.03
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Governance
The company amended its charter documents, bylaws, or changed its fiscal year.
Key Figures
New fiscal year-end: June 30
Old fiscal year-end: December 31
Transition period length: Six months
+2 more
5 metrics
New fiscal year-end
June 30
Board-approved change on May 18, 2026
Old fiscal year-end
December 31
Replaced by June 30 year-end
Transition period length
Six months
January 1, 2026 through June 30, 2026
Transition report form
Form 10-KT
For six-month period ending June 30, 2026
First quarter under new year
Quarter ending September 30, 2026
First quarterly report under new fiscal year
Key Terms
fiscal year-end, transition report on Form 10-KT, Sections 13 or 15(d) of the Securities Exchange Act of 1934, periodic reports
4 terms
fiscal year-end financial
"approved a change in the Company’s fiscal year-end from December 31 to June 30"
transition report on Form 10-KT regulatory
"including a transition report on Form 10-KT for the six-month transition period"
A transition report on Form 10-KT is an SEC filing companies submit when they change their fiscal year, providing audited financial statements and management discussion for the shortened transition period between the old and new year-ends. Investors use it like a bridge report: it fills the gap so you can compare results across different reporting calendars, spot one-time adjustments or timing shifts that affect earnings, and judge whether the change reflects operational or accounting shifts that could influence valuation.
Sections 13 or 15(d) of the Securities Exchange Act of 1934 regulatory
"file all required periodic reports under Sections 13 or 15(d) of the Securities Exchange Act of 1934"
periodic reports regulatory
"plans to file all required periodic reports under Sections 13 or 15(d)"
Regularly scheduled documents that a publicly traded company must provide to disclose its financial results, business operations, risks and significant events — like a report card showing revenue, profits, cash flow and key changes over a set period. Investors use these reports to judge a company's health and trends, compare performance over time, and make informed buy, hold or sell decisions; they act as a routine check-up for financial transparency.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What change did AnaptysBio (ANAB) announce regarding its fiscal year?
AnaptysBio is changing its fiscal year-end from December 31 to June 30. The board approved this change on May 18, 2026, shifting the company’s annual reporting cycle and aligning future financial reporting with the new June 30 year-end structure.
When will AnaptysBio’s new fiscal year begin after this change?
The company’s next fiscal year will begin on July 1, 2026. This new fiscal year follows a six-month transition period and will establish June 30 as the new fiscal year-end for AnaptysBio’s ongoing financial reporting obligations.
What transition report will AnaptysBio (ANAB) file for 2026?
AnaptysBio plans to file a transition report on Form 10-KT. This report will cover the six-month period from January 1, 2026 through June 30, 2026 under Sections 13 or 15(d) of the Securities Exchange Act of 1934.
How will AnaptysBio’s quarterly reporting schedule change after the fiscal year shift?
AnaptysBio will file quarterly reports based on the new fiscal year. The first quarterly report under this schedule will cover the quarter ending September 30, 2026, reflecting the new July 1 to June 30 fiscal year structure.
Does the AnaptysBio fiscal year change affect its Exchange Act reporting obligations?
The company will continue to file all required periodic reports under the Exchange Act. This includes the special Form 10-KT for the transition period and subsequent quarterly reports aligned with the new June 30 fiscal year-end.
AI-generated analysis. How Rhea-AI works. Not financial advice.
